先进的AI技术用于对阿尔茨海默病和轻度认知障碍进行分类
Sophie Tascedda1,2,3, Pierfrancesco Sarti4,5, Veronica Rivi4
1Plateforme de Bioinformatique, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.
Frontiers in aging neuroscience
|December 16, 2024
概括
人工智能模型,包括图形神经网络和多层感知器,可以改善阿尔茨海默病 (AD) 和轻度认知障碍 (MCI) 的诊断. 这些人工智能工具提供客观的患者数据分析,减少误诊,并使得更早,个性化干预.
科学领域:
- 神经科学是一个神经科学.
- 人工智能的人工智能
- 医学诊断 医学诊断 医学诊断
背景情况:
- 区分阿尔茨海默氏病 (AD) 和轻度认知障碍 (MCI) 是具有挑战性的,因为症状重叠和缺乏生物标志物.
- 全球人口老龄化需要提高认知障碍的诊断准确度.
- 当前的诊断方法往往导致错误诊断,突出了对先进技术的需求.
研究的目的:
- 评估人工智能模型在区分AD和MCI方面的有效性.
- 探索AI在提高认知障碍诊断准确度方面的潜力.
主要方法:
- 使用了图形神经网络 (GNN),多层感知子 (MLP) 和图形注意力网络 (GAT).
- GNNs将患者数据建模为图形,通过共享特征识别关系.
- MLP和GAT分析了分类和回归任务的离散数据,对模型的准确性,精度和回忆进行了评估.
主要成果:
- 人工智能模型提供了一个客观的框架,用于将患者数据与参考人群进行比较.
- 这种方法提高了AD和MCI之间的准确差异化.
- 改善了风险分层和支持个性化治疗策略.
结论:
- 将GNN和MLP等AI方法集成到临床实践中可以提高AD和MCI诊断.
- 这些计算技术有望减少诊断错误.
- 早些时候,预计人工智能促进的更精确的干预措施将改善患者的治疗结果.
更多相关视频
08:43Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
Published on: August 7, 2017
7.8K
09:47Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
949
相关概念视频
Alzheimer's Disease: Overview
444
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
444
Alzheimer's Disease: Treatment
162
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
162
Dementia
94
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
94
